Two clinical studies have identified mutations affecting the EGF receptor in lung cancers from patients who respond robustly to gefitinib, a small-molecule inhibitor of the receptor tyrosine kinase. This work highlights the importance of conducting clinical trials with an eye to delivering molecule-targeted therapeutics to those patients most likely to benefit.
